Triple-negative breast cancer (TNBC) lacks ER, PR and HER2 expression, represents ~10–20% of invasive breast cancers, and is clinically aggressive with limited targeted treatment options. Its pronounced molecular heterogeneity challenges single-marker diagnostics, motivating the development of robus...
ORGANISM(S): Homo sapiens (Human)